Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: J Invest Dermatol. 2015 Feb 3;135(5):1454–1456. doi: 10.1038/jid.2015.13

Fig 2. The source of the suppressive factor is not complement, IgE, or IgG autoantibody.

Fig 2

FcεRI mediated BHR suppression does not appear to be affected by a) serum IgE depletion by immunoadsorption (n=4), or b) heat inactivation of IgE and complement (n=3). The 3 sera used in figure 2a contained 33, 212, and 355 ng/ml of IgE and after immunoadsorption, levels were reduced levels to 2% of original values. c) Serum from patients pre and post omalizumab therapy (n=6) showed no differences in the degree of histamine suppression observed. d) IgG was depleted from active CIU/CSU serum using protein G Sepharose, and evaluated in comparison to untreated serum for BHR suppression (n=3). No statistical differences were seen among the active, IgG depleted, or sham depleted sera.